EP1851244A4 - Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon - Google Patents

Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon

Info

Publication number
EP1851244A4
EP1851244A4 EP05723079A EP05723079A EP1851244A4 EP 1851244 A4 EP1851244 A4 EP 1851244A4 EP 05723079 A EP05723079 A EP 05723079A EP 05723079 A EP05723079 A EP 05723079A EP 1851244 A4 EP1851244 A4 EP 1851244A4
Authority
EP
European Patent Office
Prior art keywords
treatement
antibody
cancer
agent
glycosylation variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05723079A
Other languages
English (en)
French (fr)
Other versions
EP1851244A1 (de
Inventor
Scott E Strome
Daniel Schindler
Lieping Chen
Harry Meade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
rEVO Biologics Inc
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Priority to EP11173253A priority Critical patent/EP2399935A3/de
Publication of EP1851244A1 publication Critical patent/EP1851244A1/de
Publication of EP1851244A4 publication Critical patent/EP1851244A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05723079A 2005-02-15 2005-02-15 Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon Withdrawn EP1851244A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11173253A EP2399935A3 (de) 2005-02-15 2005-02-15 Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/004739 WO2006088447A1 (en) 2005-02-15 2005-02-15 An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof

Publications (2)

Publication Number Publication Date
EP1851244A1 EP1851244A1 (de) 2007-11-07
EP1851244A4 true EP1851244A4 (de) 2009-04-15

Family

ID=36916751

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05723079A Withdrawn EP1851244A4 (de) 2005-02-15 2005-02-15 Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon
EP11173253A Withdrawn EP2399935A3 (de) 2005-02-15 2005-02-15 Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11173253A Withdrawn EP2399935A3 (de) 2005-02-15 2005-02-15 Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon

Country Status (2)

Country Link
EP (2) EP1851244A4 (de)
WO (1) WO2006088447A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012201010B2 (en) * 2005-10-21 2015-01-22 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
EP1945666B1 (de) * 2005-10-21 2013-03-27 GTC Biotherapeutics, Inc. Antikörper mit erweiterter antikörper-abhängiger zelltoxizitäts-aktivität sowie herstellungs- und verwendungsverfahren dafür
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
US20110229460A1 (en) * 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
EP3536708A1 (de) * 2011-04-19 2019-09-11 Pfizer Inc Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
JP2017517506A (ja) * 2014-05-21 2017-06-29 ファイザー・インコーポレイテッド 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用
CA2977257A1 (en) 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
MX2017014699A (es) 2015-05-21 2018-04-11 Alligator Bioscience Ab Polipeptidos novedosos.
EP3744340A3 (de) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
WO2017049452A1 (zh) * 2015-09-22 2017-03-30 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用
CN108424928B (zh) 2016-12-30 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018121787A1 (en) * 2016-12-30 2018-07-05 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric cd137
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
CN112867733B (zh) * 2018-10-19 2023-01-06 苏州丁孚靶点生物技术有限公司 抗cd137抗体及其应用
WO2021226883A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer submission of sequence listing on ascii text file

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016249A1 (en) * 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
WO2000029445A1 (en) * 1998-11-17 2000-05-25 Lg Chemical Limited Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
WO2003049755A1 (en) * 2001-10-09 2003-06-19 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
WO2004010947A2 (en) * 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US20040025193A1 (en) * 2002-08-01 2004-02-05 Yann Echelard Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016249A1 (en) * 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
WO2000029445A1 (en) * 1998-11-17 2000-05-25 Lg Chemical Limited Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
WO2003049755A1 (en) * 2001-10-09 2003-06-19 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
WO2004010947A2 (en) * 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US20040025193A1 (en) * 2002-08-01 2004-02-05 Yann Echelard Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transfer

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
HORAN-HAND P ET AL: "COMPARATIVE BIOLOGICAL PROPERTIES OF A RECOMBINANT CHIMERIC ANTI-CARCINOMA MAB AND A RECOMBINANT AGLYCOSYLATED VARIANT", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 35, no. 3, 1992, pages 165 - 174, XP001539281, ISSN: 0340-7004 *
HUMPHREYS D P ET AL: "THERAPEUTIC ANTIBODY PRODUCTION TECHNOLOGIES: MOLECULES, APPLICATIONS, EXPRESSION AND PURIFICATION", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 4, no. 2, 1 March 2001 (2001-03-01), pages 172 - 185, XP008016086, ISSN: 1367-6733 *
MEADE H M ET AL: "Expression of recombinant proteins in the milk of transgenic animals", GENE EXPRESSION SYSTEMS. USING NATURE FOR THE ART OF EXPRESSION, XX, XX, 1 January 1999 (1999-01-01), pages 399 - 427, XP009088286 *
OKAZAKI A ET AL: "Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcgammaRIIIa", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 336, no. 5, 5 March 2004 (2004-03-05), pages 1239 - 1249, XP004490178, ISSN: 0022-2836 *
POLLOCK D P ET AL: "Transgenic milk as a method for the production of recombinant antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 147 - 157, XP004186081, ISSN: 0022-1759 *
See also references of WO2006088447A1 *
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002495886, ISSN: 0021-9258, [retrieved on 20001128], DOI: 10.1074/JBC.M009483200 *
SHIELDS ROBERT L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002442140, ISSN: 0021-9258 *
W. LIN ET AL: "Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies", BLOOD, vol. 112, no. 3, 1 August 2008 (2008-08-01), pages 699 - 707, XP055037053, ISSN: 0006-4971, DOI: 10.1182/blood-2007-11-122465 *
WRIGHT A ET AL: "EFFECT OF ALTERED CH2-ASSOCIATED CARBOHYDRATE STRUCTURE ON THE FUNCTIONAL PROPERTIES AND IN VIVO FATE OF CHIMERIC MOUSE-HUMAN IMMUNOGLOBULIN G1", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 180, no. 3, 1 September 1994 (1994-09-01), pages 1087 - 1096, XP000676306, ISSN: 0022-1007 *
ZHOU Q ET AL: "Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 117, no. 1, 20 April 2005 (2005-04-20), pages 57 - 72, XP004836787, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
WO2006088447A1 (en) 2006-08-24
EP1851244A1 (de) 2007-11-07
EP2399935A2 (de) 2011-12-28
EP2399935A3 (de) 2012-02-22

Similar Documents

Publication Publication Date Title
EP1851244A4 (de) Anti-cd137-antikörper als mittel für die behandlung von krebs, und glykosylierungsvarianten davon
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL184659A0 (en) Antibody variants and uses thereof
ZA200707339B (en) Human antibodies against rabies and uses thereof
GB0524772D0 (en) Processor and interface
IL187503A0 (en) Stable and soluble antibodies
EP1746884A4 (de) Stabilisierte hyaluronanpräparate und damit zusammenhängende verfahren
EP1968649A4 (de) Protein-nanoteilchen und ihre verwendung
EP1747284A4 (de) Diagnose und therapeutika gegen krebs
IL188031A0 (en) Use of thiazole derivatives and analogues in the treatment of cancer
EP1874800A4 (de) Diagnostische und therapeutische mittel
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
EP1841467A4 (de) Kombinationskrebstherapie mit anti-psma-antikörpern
EP2123266A4 (de) Therapeutisches krebsmittel und anti-karzinogenes mittel
ZA200800243B (en) Use of thiazole derivatives and analogues in the treatment of cancer
IL181300A0 (en) Photosensitizer formulations and uses thereof
EP1871166A4 (de) Karzinomimpfstoffe und therapeutische verfahren
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1904088A4 (de) Zusammensetzungen und verfahren für die krebsbehandlung
EP1786415A4 (de) Mittel zur modulierung des stoffwechsels und verwendungen dafür
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB2448627B (en) Combination therapy and antibody panels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090317

17Q First examination report despatched

Effective date: 20090629

DAC Divisional application: reference to earlier application (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130319